Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 123 |
| Active Pipeline (Recruiting Now) | 67 (32) |
| Completed vs Stopped Early | 46 / 8 (6.5%) |
| Median Closed Actual Enrollment | 112 participants |
| Physical Hospital Site Disclosure | 87.4% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Zhejiang Cancer Hospital | Hangzhou, Zhejiang | 12 |
| Fudan University Shanghai Cancer Center | Shanghai, Shanghai Municipality | 10 |
| Hunan Cancer Hospital | Changsha, Hunan | 9 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06196203 | A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes | Phase II | RECRUITING |
| NCT07010263 | A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurr | Phase III | RECRUITING |
| NCT07700979 | Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Par | Phase III | RECRUITING |
| NCT05859750 | A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer | Phase II | RECRUITING |
| NCT05235516 | A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer | Phase III | ACTIVE NOT RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Akeso Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.